HONG KONG – China has indicted two investigators linked to the bribery scandal that has rocked Glaxosmithkline plc. The couple – 58-year-old British man Peter William Humphrey and his 61-year-old American Chinese wife Yu Yingzeng – was arrested in Shanghai last August.
HONG KONG – Over the next decade, competition for market share between biosimilar products and their originator drugs is likely to grow fierce, but price differentiation may not be enough to ensure sales.
HONG KONG – Over the next decade, competition for market share between biosimilar products and their originator drugs is likely to grow fierce, but price differentiation may not be enough to ensure sales.
SEOUL, South Korea – With one eye firmly planted on future economic growth, South Korea is taking steps to boost its biotechnology industry by putting resources into a wide range of traditional and emerging subsectors from biosimilars to stem cell treatments.
SEOUL, South Korea – Promising as the biosimilar market appears today, a consolidation that leaves only a handful of global players may be inevitable and the prospects may not be as rosy as they seem, said drug company executives at Bio Korea 2014.
SEOUL, South Korea – With one eye firmly planted on future economic growth, South Korea is taking steps to boost its biotechnology industry by putting resources into a wide range of traditional and emerging subsectors from biosimilars to stem cell treatments.
SEOUL, South Korea – Promising as the biosimilar market appears today, a consolidation that leaves only a handful of global players may be inevitable and the prospects may not be as rosy as they seem, said drug company executives at Bio Korea 2014.
India is considering waiving a global patent for cancer drug dasatanib under provisions of the country's Patent Act that allow it to make the move for public noncommercial use.
India is considering waiving a global patent for cancer drug dasatanib under provisions of the country's Patent Act that allow it to make the move for public noncommercial use.
HONG KONG – A Hong Kong-based biotechnology company that specializes in in-licensing products for marketing in China will work with a partner in South Korea and one in Europe in a late-stage clinical development program for the oncolytic immunotherapy Pexa-Vec (JX-594/TG6006).
